Aptamer Signs Therapeutic Development Agreement with Invizius

Aptamer signs therapeutic development agreement with Invizius

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce that it has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology company focused on second-generation complement system therapies for inflammatory, fibrotic, and autoimmune diseases.

Aptamer Signs Therapeutic Development Agreement with Invizius

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce that it has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology company focused on second-generation complement system therapies for inflammatory, fibrotic, and autoimmune diseases.

Aptamer Signs Therapeutic Development Deal With Invizius

Aptamer Group plc (LON:APTA), the developer of next-generation synthetic binders for the life sciences industry, has announced that it has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology company focused on second-generation complement system therapies for inflammatory, fibrotic, and autoimmune diseases. The complement system is a critical part of the immune response, but its dysregulation is implicate…